Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04675086 Withdrawn - Covid19 Clinical Trials

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

Start date: January 2021
Phase: Phase 3
Study type: Interventional

This is a Randomized, Open-Label Study of the Efficacy and Safety of Aralast NP Infusion Therapy with Antiviral Treatment and standard of care versus Antiviral Treatment and standard of care (control group) in Hospitalized Patients with Pneumonia and COVID-19 Infection.

NCT ID: NCT04584697 Withdrawn - Covid19 Clinical Trials

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19

Start date: December 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, placebo-controlled study to assess the safety, PK profile, and efficacy of COVI-AMG in subjects with COVID-19.

NCT ID: NCT04584437 Withdrawn - Covid19 Clinical Trials

Treatment of Covid-19 Using Infrared and/or Vitamin C

Start date: January 31, 2021
Phase: N/A
Study type: Interventional

The human immune system is enhanced by exposure to infrared radiation with the wavelength of 5 microns to 20 microns. Humans, at normal body temperature, radiate most strongly in the infrared at a wavelength of about 10 microns. Infrared energy sustains life and can be used to treat and prevent diseases, including Covid-19 pandemic. High doses of Vitamin C kills pathogens, viruses and disease-causing microbes. High doses of Vitamin C increases one's immune system. Vitamin C is an anti-oxidant, produces hydrogen peroxide and removes free radicals from the body. It is proposed that infrared radiotherapy by itself or the use of high doses of Vitamin C as a stand alone dietary supplement or a combination of infrared radiotherapy and Vitamin C can be used for the prevention and treatment of coronavirus infections.

NCT ID: NCT04579458 Withdrawn - Covid19 Clinical Trials

Assessment of COVID-19 in Tearfilm

Start date: December 28, 2020
Phase:
Study type: Observational

To assess the co-relation of COVID-19 in nasopharyngeal swabs and tears or saliva, and to determine duration of COVID-19 activity in ocular fluid and saliva by serial tests over 3 months.

NCT ID: NCT04570449 Withdrawn - Covid19 Clinical Trials

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

Start date: November 2020
Phase: Early Phase 1
Study type: Interventional

The current research is a pilot study to determine the feasibility of recruiting and retaining 40 participants diagnosed with COVID-19. The purpose is to observe the early use of fluoxetine (commonly known as Prozac) to reduce the severity of the COVID-19 illness. Fluoxetine is a drug that has been approved by the U.S. Food and Drug Administration (FDA) since 1987 for various mental health disorders.

NCT ID: NCT04532554 Withdrawn - Covid19 Clinical Trials

Growth Hormone in Obese Cases With Covid-19

Start date: October 26, 2020
Phase: Phase 4
Study type: Interventional

The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.

NCT ID: NCT04452643 Withdrawn - Covid19 Clinical Trials

Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel

Bacmune
Start date: October 2020
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to assess the effect of immunotherapy with the bacterial preparation MV130 on the spread and course of SARS-CoV-2 infection in highly exposed subjets, as is the case with healthcare personnel.

NCT ID: NCT04392128 Withdrawn - COVID19 Clinical Trials

Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)

HYACINTHE
Start date: September 2, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of this phase 2, multicentric, placebo-controlled double-blind, randomized study is to evaluate the efficacy of the combination of hydroxychloroquine and azithromycine on the viral load drop at day 5 among patients with COVID-19 and hematological malignancies.

NCT ID: NCT04379492 Withdrawn - COVID19 Clinical Trials

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

Start date: May 5, 2020
Phase: Phase 2
Study type: Interventional

This study is being done to see if hydroxychloroquine is an effective treatment for COVID-19.

NCT ID: NCT04365231 Withdrawn - COVID19 Clinical Trials

Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial

HASCOPT
Start date: April 1, 2020
Phase: Phase 3
Study type: Interventional

Up to date, and since December 31st 2019, 2 520 522 cases of COVID-19 including 176 786 deaths, have been reported worldwide. Global efforts are made to save lives and decrease morbidity by evaluating therapeutic strategies. Pregnant women with COVID-19 are at high-risk of severe complications and mortality from COVID-19 infection, due to physiologic and immune changes occurring during pregnancy. These risks include development of maternal hypoxemic respiratory failure due to severe pneumonia, hospitalization in intensive care, death; but also, fetal morbidity-mortality with chronic and/or acute fetal distress, intrauterine growth retardation, intrauterine death and neonatal morbidity, mainly due to induced preterm birth and maternal-fetal transmission. Knowledge of these epidemiologic facts on SARS-Cov-2 infection in pregnant women is currently limited to small case-series. No drug has demonstrated solid evidence in treating SARS-Cov-2 virus. Nevertheless, in vitro studies and tests in COVID-19 positive patients treated with hydroxychloroquine and azithromycin merit further evaluation. Pregnant women are systematically excluded from drug trials, and treatment options for this high-risk population remain untested. The aim of this study is to screen pregnant women presenting minor symptoms, for COVID-19 and to evaluate efficacy of hydroxychloroquine-azithromycin treatment in preventing aggravation of symptoms with development of hypoxemic respiratory failure and complications of pregnancy.